Gilteritinib as a single agent demonstrated a higher cCR rate (34.0% vs. 15.3%) and longer survival (median OS of 9.3 months vs. 5.6 months; HR for death, 0.64; 95% CI, 0.49–0.83; p < 0.001) compared with salvage chemotherapy in the phase III ADMIRAL trial including 247 R/R FLT3-mutated AML patients [37]. This evidence concerns the gene FLT3 and acute myeloid leukemia.